Apellis Pharmaceuticals announced that SYFOVRE preserved visual function at 36 months in patients with geographic atrophy secondary to age-related macular degeneration. These positive data from the GALE long-term extension study were presented at the Clinical Trials at the Summit Meeting on June 8 in Park City, Utah. In a prespecified microperimetry endpoint, patients developed fewer new scotomatous points with 36 months of both continuous monthly and every-other-month treatment compared to patients from the sham crossover group. Scotomatous points measure areas of the retina that have lost all light sensitivity and therefore are no longer functioning.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APLS:
- Apellis Pharmaceuticals to Host a Fireside Chat at the Goldman Sachs 45th Annual Global Healthcare Conference
- Apellis initiated with a Neutral at Piper Sandler
- Apellis shares ‘undervalued’ at current levels, says UBS
- Apellis trial results reaffirm confidence ahead of VALIANT readout, says Stifel
- Positive One-Year Data from Phase 2 Study of Pegcetacoplan in Post-Transplant Recurrence of C3G and IC-MPGN Presented as Late-Breaker at ERA Congress